[Nonmyeloablative allogeneic peripheral blood stem cell transplantation of renal cell carcinoma]

Nihon Rinsho. 2003 Sep;61(9):1607-12.
[Article in Japanese]

Abstract

We presented three cases with refractory metastatic renal cell carcinomas who underwent nonmyeloablative allogeneic peripheral blood stem cell transplantation(PBSCT). A fludarabine and cyclophosphamide-based regimen was used. Complete donor-T-cell chimerism was established at day 94, 40, 52 after PBSCT in each case. GVHD occurred at day 183, 53, 75. In Case 1 and Case 3 apparent GVT effects reduced the metastases at day 212, 261 and let them live longer than expected. Case 2 died at day 69 before GVT effect appeared, because the case was so-called rapid growth type. Histological examinations in Case 1 and Case 3 showed infiltration of lymphocytes disrupting the foci of renal cell carcinomas which was considered as findings of GVT effects.

Publication types

  • Case Reports
  • English Abstract
  • Review

MeSH terms

  • Aged
  • Carcinoma, Renal Cell / therapy*
  • Cyclophosphamide / therapeutic use
  • Female
  • Graft vs Host Disease / etiology
  • Graft vs Host Disease / prevention & control
  • Graft vs Tumor Effect
  • Humans
  • Kidney Neoplasms / therapy*
  • Male
  • Middle Aged
  • Peripheral Blood Stem Cell Transplantation*
  • Prognosis
  • Transplantation Chimera
  • Transplantation Conditioning*
  • Transplantation, Homologous
  • Vidarabine / analogs & derivatives*
  • Vidarabine / therapeutic use

Substances

  • Cyclophosphamide
  • Vidarabine
  • fludarabine